aripiprazole lauroxil LAI
Selected indexed studies
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. (Am J Psychiatry, 2020) [PMID:31838873]
- Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. (CNS Drugs, 2021) [PMID:33507525]
- Aripiprazole Lauroxil: A Review in Schizophrenia. (Drugs, 2017) [PMID:29177572]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Aripiprazole Lauroxil: A Review in Schizophrenia. (2017) pubmed
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. (2020) pubmed
- Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. (2021) pubmed
- Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. (2023) pubmed
- Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents. (2016) pubmed
- Appropriate use of single-dose injectable aripiprazole lauroxil in the treatment of schizophrenia. (2024) pubmed
- Initiation of Aripiprazole Lauroxil Long-Acting Injectable in Adolescents During Hospitalization: A Case Series. (2023) pubmed
- Aripiprazole Lauroxil NanoCrystal (®) Dispersion Technology (Aristada Initio (®) ). (2018) pubmed
- Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique. (2019) pubmed
- Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia. (2021) pubmed